You are here
Management of toxicities in special cases
Presentation by Dr. Benjamin Besse at the TAO Congress on 19/20 November 2015
Dr. Benjamin Besse is Head of the Thoracic Unit at the cancer-research institute and oncology health centre Institut Gustave Roussy. He provides an overview of disease segmentation based on oncogenic events, non-small-cell lung carcinoma (NSCLC) heterogeneity and EGFR mutations in lung cancer. After reviewing survival figures from several clinical trials, he presents clinical cases from his institute. Various therapeutic substances were used, for example bevacizumab, cisplatin, crizotinib, erlotinib, gemcitabine, paclitaxel, pemetrexed, vemurafenib, etc. Dr. Besse discusses the toxicities which occurred in these cases, such as rash, dry skin, alopecia, dyspnea, cough and hepatotoxicity, as well as the supportive care which they required. With new therapies available, many patients receive long-term treatment which leads to chronic toxicities; in view of the clinical case in which the patient has been receiving the epidermal growth factor receptor (EGFR) inhibitor erlotinib for 8.5 years, Dr. Besse discusses the question: When to stop?
The presentation is followed by comments from Dr. Richard Gralla (A. Einstein School of Medicine, New York, USA).
Dr. Benjamin Besse, Institut Gustave Roussy, Villejuif, France